| 摘要 |
The present invention provides compounds of formula I, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting kinase (e.g., GSK3 (e.g., GSK3α or GSK3&bgr;) or CK1) activity. The present invention further provides methods of using the compounds described herein for treating kinase-mediated disorders, such as neurological diseases, psychiatric disorders, metabolic disorders, and cancer. |
| 申请人 |
THE BROAD INSTITUTE, INC.;DANA-FARBER CANCER INSTITUTE, INC.;THE GENERAL HOSPITAL CORPORATION |
发明人 |
WAGNER, FLORENCE, FEVRIER;PAN, JENNIFER, Q.;DANDAPANI, SIVARAMAN;GERMAIN, ANDREW;HOLSON, EDWARD;MUNOZ, BENITO;NAG, PARTHA, P.;WEIWER, MICHEL;LEWIS, MICHAEL, C.;HAGGARTY, STEPHEN, J.;BISHOP, JOSHUA, A.;STEGMAIER, KIMBERLY;BANERJI, VERSHA |
